Diagnosing recurrent acute myeloid leukemia is a critical step in managing this challenging blood cancer that has returned after treatment. Understanding when and how to seek diagnostic testing can help patients and their healthcare teams make informed decisions about the next steps in care.

Introduction: Who Should Undergo Diagnostics

When acute myeloid leukemia comes back after treatment, knowing when to seek diagnostic testing becomes essential for determining the best course of action. Recurrent, or relapsed, acute myeloid leukemia means the cancer has returned after a period of remission, when no leukemia cells were detected in the blood or bone marrow and symptoms had disappeared^[1]. If the cancer didn’t respond to initial treatment and complete remission was never achieved because chemotherapy didn’t eliminate enough leukemia cells, this is called refractory disease^[3].

People who have been treated for acute myeloid leukemia should be alert to symptoms that might signal the disease has returned. These warning signs often mirror the original symptoms experienced at first diagnosis. When symptoms appear, it’s important to contact your healthcare team right away rather than waiting to see if they improve on their own, because acute myeloid leukemia is an aggressive cancer that can worsen quickly without treatment^[1].

The symptoms that should prompt you to seek diagnostic evaluation include ongoing tiredness that doesn’t improve with rest, unusual bruising that appears without injury, or bleeding that occurs more easily than normal, such as frequent nosebleeds or bleeding gums. You might notice small red spots appearing on your skin, called petechiae (tiny red dots caused by bleeding under the skin), or experience repeated infections that don’t clear up as expected. Other concerning signs include fever without an obvious cause, night sweats that soak through clothing or bedding, swollen glands in the neck or other areas, persistent headaches, shortness of breath during normal activities, or aching in your bones, back, or abdomen^[1][7].

Even if you’re not experiencing obvious symptoms, regular follow-up appointments with your healthcare team are important after completing treatment. Most relapses happen within the first two years after finishing initial treatment, though they can occur later. After five years in remission, the chance of relapse becomes extremely small^[13]. Your doctor will schedule periodic check-ups to monitor your blood counts and overall health, which can detect changes before symptoms develop.

Diagnostic Methods for Detecting Relapsed Disease

When there’s concern that acute myeloid leukemia may have returned, doctors use several tests to confirm whether the cancer is actually back and to understand its characteristics. These diagnostic procedures help distinguish relapsed leukemia from other medical conditions that might cause similar symptoms, and they provide crucial information about the genetic makeup of the cancer cells, which can guide treatment decisions.

Blood tests are typically the first diagnostic step when relapse is suspected. Your doctor will order complete blood counts to examine the levels of different blood cells in a sample taken from your vein. In relapsed acute myeloid leukemia, these tests can reveal abnormal numbers of normal blood cells and may show the presence of leukemia cells circulating in the bloodstream^[7]. The blood sample is examined under a microscope to look for blasts (immature, abnormal white blood cells that characterize acute myeloid leukemia).

A bone marrow test is usually necessary to definitively diagnose relapsed acute myeloid leukemia. During this procedure, doctors remove a small sample of bone marrow, typically from the hip bone, to examine how many leukemia cells are present and to check for genetic changes in the cancer cells. This test provides more detailed information than blood tests alone because the bone marrow is where blood cells are produced, and it’s the primary site where leukemia cells accumulate^[7]. The bone marrow sample is analyzed in several ways: cells are counted and examined under a microscope, and sophisticated tests look for specific genetic mutations and chromosomal abnormalities (changes in the structures that carry genetic information) that can affect how the disease behaves and responds to treatment.

At the time of relapse, doctors typically perform a new mutational screening and cytogenetic analysis, which means they examine the genetic makeup of the leukemia cells in detail. This is important because the cancer cells may have changed since the initial diagnosis, a process called clonal evolution (when cancer cells develop new genetic changes over time). Understanding these changes helps doctors select the most appropriate treatment approach^[11].

If you experience symptoms such as persistent headaches or if doctors suspect the leukemia may have spread to your brain or spinal cord, they may perform a lumbar puncture (also called a spinal tap). During this procedure, a small amount of the fluid that surrounds your spinal cord is removed through a needle inserted into your lower back. The fluid is then checked for the presence of leukemia cells^[7][10].

Imaging tests may also be used as part of the diagnostic workup. A chest X-ray can help doctors look for enlarged lymph nodes in your chest or other changes that might be caused by leukemia. These imaging studies help determine if the cancer has spread beyond the blood and bone marrow to other parts of the body^[7].

The combination of these diagnostic tests provides a complete picture of whether the leukemia has returned, how extensive it is, and what characteristics the cancer cells have. This comprehensive evaluation is essential because different patterns of relapse and different genetic features of the cancer cells require different treatment approaches. Some people may have refractory disease rather than relapsed disease, and the distinction between these two situations—along with the detailed genetic information—helps healthcare teams recommend the most appropriate next steps in care.

Diagnostics for Clinical Trial Qualification

When someone experiences relapsed or refractory acute myeloid leukemia, participating in a clinical trial should be considered a priority option. Clinical trials test new treatments or new combinations of existing treatments that may offer benefits beyond what standard therapies provide. However, to participate in these research studies, patients must meet specific criteria, which are determined through various diagnostic tests and assessments^[11].

The diagnostic tests used to qualify patients for clinical trials are similar to those used for standard diagnosis, but they may be more extensive or require more detailed analysis. Blood tests and bone marrow examinations are fundamental requirements for most clinical trials involving recurrent acute myeloid leukemia. These tests confirm the diagnosis and provide baseline measurements that researchers will use to evaluate how well the treatment works.

Genetic and molecular testing plays a particularly important role in determining eligibility for many clinical trials. Researchers have identified specific genetic mutations and molecular markers in acute myeloid leukemia cells that can predict which patients are most likely to benefit from targeted therapies. For example, some clinical trials specifically enroll patients whose leukemia cells have mutations in genes called FLT3 or IDH1/IDH2. Testing for these mutations requires specialized laboratory analysis of blood or bone marrow samples. Other trials may look for the presence of specific proteins on the surface of leukemia cells, such as CD33, which certain drugs are designed to target^[3].

Performance status assessment is another critical component of clinical trial eligibility. Doctors evaluate how well you can perform daily activities and how much the disease is affecting your physical functioning. This assessment helps determine whether you’re strong enough to tolerate the treatment being tested in the trial. Some trials accept patients with any performance status, while others require participants to be relatively fit and able to care for themselves with minimal assistance.

Additional diagnostic tests may be required depending on the specific clinical trial. Some studies require imaging scans, such as CT scans or chest X-rays, to establish baseline measurements of any disease outside the bone marrow. Others may require heart function tests, such as an electrocardiogram (a test that records the electrical activity of the heart) or an echocardiogram (an ultrasound examination of the heart), because some treatments can affect heart function and researchers need to know your heart is healthy enough to safely receive the treatment.

Kidney and liver function tests are commonly required for clinical trial participation. These blood tests measure how well your kidneys and liver are working, which is important because these organs process and eliminate many medications from your body. If these organs aren’t functioning properly, you may not be able to safely receive certain treatments being tested in clinical trials.

For patients who previously underwent stem cell transplantation and then experienced relapse, additional diagnostic criteria may apply. The timing of relapse after transplant, the presence of graft-versus-host disease (a condition where transplanted cells attack the patient’s body), and the availability of the original stem cell donor for additional procedures may all factor into clinical trial eligibility.

Documentation of treatment history is essential for clinical trial qualification. Researchers need detailed records of all previous treatments you received, including the specific chemotherapy drugs used, their doses, how long you were in remission, and how your disease responded to those treatments. This information helps ensure that the trial is appropriate for your situation and that you haven’t already received treatments that would interfere with the study intervention^[3].